EUVIMEDEUVIMED entdecken
Crossref

The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas

Gozde Yazici iD, Serkan Akin, Alper Kahvecioglu iD, Ecem Yigit iD, Fatma Alev Turker, Ferah Yildiz iD

Head & Neck · 2025

DOI: 10.1002/hed.27976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Gozde Yazici und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Orbital Neoplasms, Lymphoma, Eye Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy.

Methods

A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted.

Results

Most patients (87%) had early‐stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow‐up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five‐year overall and disease‐free survival (DFS) rates were 96.2% and 83.6%. Early‐stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT‐related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients.

Conclusions

RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early‐stage patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orbital NeoplasmsLymphomaEye NeoplasmsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedAdultAged, 80 and overDisease-Free SurvivalTreatment OutcomeRadiotherapy DosageYoung AdultNeoplasm StagingNeoplasm Recurrence, LocalFollow-Up Studies

Stichwörter der Autor:innen

indolent lymphomalymphomaorbital lymphomaradiotherapyrituximab

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
  • Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.

ORCID-Profile: Gozde Yazici, Alper Kahvecioglu, Ecem Yigit, Ferah Yildiz

Zitieren

APA

Yazici, G., Akin, S., Kahvecioglu, A., Yigit, E., Turker, F. A., & Yildiz, F. (2025). The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas. Head & Neck. https://doi.org/10.1002/hed.27976

Vancouver

Yazici G, Akin S, Kahvecioglu A, Yigit E, Turker FA, Yildiz F. The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas. Head & Neck. 2025. doi:10.1002/hed.27976

BibTeX
@article{Yazici2025,
  author = {Yazici, Gozde and Akin, Serkan and Kahvecioglu, Alper and Yigit, Ecem and Turker, Fatma Alev and Yildiz, Ferah},
  title = {The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27976}
}
Kostenlos starten →